EORTC protocol 40051 - BOS

Randomized phase II trial evaluating the feasibility and tolerance of the combination of FOLFOX with cetuximab and the combination of FOLFOX with cetuximab and bevacizumab as perioperative treatment in patients with resectable liver metastases from colorectal cancer (BOS).
Trial StatusClosed for recruitment
DatesDate of activation: 04-Jan-07
Closed on : 12-Jun-09
Data management at EORTCFull
Phase2
Randomized trialYes
TypePeriadjuvant
Targeted Sample sizeEORTC Groups: 100 - All Groups: 100
Number of steps1
DrugFluorouracil
Bevacizumab
Cetuximab
Leucovorin
Oxaliplatin
Study StaffBernard Nordlinger (Study Coordinator) - CHU Ambroise Pare AP-HP, Boulogne-Billancourt
Murielle Mauer (Statistician) - EORTC Headquarters, Brussels
Marie-Ange Lentz (Data Manager) - EORTC Headquarters, Brussels
Michel Praet (Project Manager) - EORTC Headquarters, Brussels, michel.praet( at )eortc.be, +32 27741672
Type of cancerLiver
Colorectal
Participating GroupsEORTC Gastrointestinal Tract Cancer Group(Coordinating Group)
Protocol summaryCancer.gov (PDQ)
ClinicalTrials.gov
NCT numberNCT00438737
EudraCT2005-002825-29
Protocol documents in PDF
(requires password)
Study documentation
Back to Protocol section